Benzopyran derivatives, potassium channel activators, relaxant activity on smooth muscle, inhibitors of insulin secretion

The patented technology relates to novel benzopyran derivatives, to their method of production, to pharmaceutical composition comprising the derivatives and their therapeutic uses. ATP-sensitive potassium channels (KATP channels) are present in multiple cell types including endocrine cells, skeletal and smooth muscle cells, cardiac cells and central neurons. KATP channels are involved in main physiological processes such as hormone secretion, smooth muscle cell contractile activity, myocardial protection and neurotransmitters release. Several compounds are known to activate KATP channels and have been named "potassium channel openers" (PCOs). Potassium channel openers are known to be able to relax vascular smooth muscles and have therefore been used for the treatment of hypertension. We have now found benzopyran derivatives useful as potassium channel activators which surprisingly are active on the pancreatic endocrine tissue as inhibitors of insulin secretion. The new benzopyran derivatives could be useful as therapeutically acceptable substances, preferably in the treatment of hyperinsulinaemia and obesity as well as in the treatment or prevention of diabetes.

Early Stage

EP, US, CA, JP filing under prosecution

Opportunities are available